Dianthus Therapeutics, Inc. (DNTH)

NASDAQ: DNTH · IEX Real-Time Price · USD
30.00
-0.60 (-1.96%)
Mar 28, 2024, 4:00 PM EDT - Market closed

Company Description

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases.

It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.

Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Dianthus Therapeutics, Inc.
Dianthus Therapeutics logo
Country United States
Founded 2015
Industry Biotechnology
Sector Healthcare
Employees 53
CEO Marino Garcia M.B.A.

Contact Details

Address:
300 Technology Square, 8th Floor
Cambridge, Massachusetts 02139
United States
Phone 857-201-2700
Website dianthustx.com

Stock Details

Ticker Symbol DNTH
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001690585
ISIN Number US2528281080
SIC Code 2834

Key Executives

Name Position
Marino Garcia M.B.A. President, Chief Executive Officer, Secretary and Director
Ryan Savitz Chief Financial Officer and Chief Business Officer and Treasurer
Edward G. Carr Chief Accounting Officer
Judson Taylor Head of Technical Operations
Dr. Jeffrey Stavenhagen Ph.D. Chief Scientific Officer
Jennifer Davis Ruff Vice President and Head of Investor Relations and Corporate Affairs.
Adam M. Veness Esq. General Counsel
Kristina Maximenko Chief People Officer
Simrat Randhawa M.B.A., M.D. Chief Medical Officer
Rashieda Gluck Head of Clinical Development Operations

Latest SEC Filings

Date Type Title
Mar 27, 2024 EFFECT Notice of Effectiveness
Mar 21, 2024 S-8 Securities to be offered to employees in employee benefit plans
Mar 21, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Mar 21, 2024 10-K Annual Report
Mar 21, 2024 8-K Current Report
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 9, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 7, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933